

Supplementary Information




Figure S1. Dose-dependent growth inhibition of *Pseudomonas aeruginosa* (ATCC19660) or drug-resistant *Pseudomonas aeruginosa* (R) by incubation with TP3 or TP4 for 16 h. The data are expressed as means of three replicates. Error bars represent the standard derivation (SD). OD, optical density.




Figure S2. Kill kinetics of TP3 and TP4 against *Pseudomonas aeruginosa* (ATCC19660) and drug-resistant *Pseudomonas aeruginosa* (R). Controls were not treated with peptide. The peptide concentrations were 1 × MIC (1 ×), 4 × MIC (4 ×), or 8 × MIC (8 ×). Experiments were performed in triplicate and the bactericidal activities are presented as mean lg (CFU/mL). Error bars represent the standard deviations.




Figure S3. The effect of TP3 and TP4 on the release of DNA from *Pseudomonas aeruginosa* (ATCC19660) or drug-resistant *Pseudomonas aeruginosa* (R). Peptide concentrations used were 1 × MIC, 2 × MIC, or 4 × MIC. “Control” indicates untreated cells. The data are means of at least three independent experiments. Error bars represent the standard deviations.

Table S1. Phenotypes, genotypes, and drug resistant features of clinical bacteria isolates provided by Te-Li Chen (Taipei Veterans General Hospital) for use in this study.

Bacterial strain	Information
<i>K. pneumoniae</i> (YT 32)	Phenotype: blaAmpC (+)
	Genotype: blaAmpC (+) ESBL (+)
<i>E. coli</i> (YT 39)	Phenotype: blaAmpC (+)
	Genotype: blaAmpC (+)
<i>E. coli</i> (YT 154)	Phenotype: blaAmpC (+)
	Genotype: blaAmpC (+) ESBL (+)